Long-term safety of vedolizumab for inflammatory bowel disease.
Edward V LoftusBrian G FeaganRemo PanaccioneJean Frederic ColombelWilliam J SandbornBruce E SandsSilvio DaneseGeert R A M D'HaensDavid T RubinIra ShafranAndrejus ParfionovasRaquel RogersRichard A LirioSeverine VermeirePublished in: Alimentary pharmacology & therapeutics (2020)
The safety profile of vedolizumab remains favourable with no unexpected or new safety concerns. These results further establish the safety of vedolizumab and support its long-term use (NCT00790933/EudraCT 2008-002784-14).